She underwent
chemotherapy for her breast cancer.
她接受了化疗治疗乳腺癌。
The
chemotherapy was very tough on his hair, but he maintained his sense of humor.
化疗对他的头发影响很大，但他仍然保持着幽默感。
He's currently in the middle of a
chemotherapy cycle.
他现在正在进行一轮化疗。
The doctor prescribed a regimen of
chemotherapy and radiation therapy.
医生为他开了化疗和放疗的治疗方案。
Her side effects from
chemotherapy were manageable with medication.
她的化疗副作用通过药物得到了控制。
The patient is undergoing palliative
chemotherapy to alleviate their symptoms.
患者正在接受姑息性化疗以缓解症状。
They're researching new targeted therapies to complement
chemotherapy.
他们正在研究新的靶向疗法来辅助化疗。
He's been on maintenance
chemotherapy to prevent the recurrence of his leukemia.
他一直在进行维持性化疗以防白血病复发。
The doctor recommended a break from
chemotherapy to allow his body to recover.
医生建议他暂时停止化疗以便让身体恢复。
Many cancer survivors experience long-term side effects from
chemotherapy, but advances in treatment are improving outcomes.
许多癌症幸存者在化疗后会有长期副作用，但治疗的进步正在改善这些情况。
The supplemental new drug application for the drug in combination with chemotherapy as perioperative treatment and subsequently, monotherapy as adjuvant therapy for the treatment of adult patients with resectable stage IIIA-IIIB non-small cell lung cancer (NSCLC) has been approved by the National Medical Products Administration, the company announced Tuesday.
该公司周二宣布，国家医疗产品管理局已批准该药物与化疗联合作为围手术期治疗的补充新药申请，以及随后作为辅助治疗的单药治疗，用于治疗可切除的IIIA-IIIB期癌症（NSCLC）成年患者。
Radical surgery in combination with chemotherapy is a way to prevent recurrence, but chemotherapy alone, as preoperative neoadjuvant or postoperative adjuvant therapy, has limited clinical benefits and can only raise patients' 5-year survival rate by approximately 5 percent.
根治性手术联合化疗是预防复发的一种方法，但单独化疗作为术前新辅助或术后辅助治疗，临床益处有限，只能将患者的5年生存率提高约5%。
The Chinese biotech and its US partner Coherus BioSciences Inc jointly announced on Oct 27 that the US FDA approved Loqtorzi (toripalimab-tpzi) in combination with other drugs for the first-line treatment of adults with metastatic or recurrent locally advanced metastatic nasopharyngeal carcinoma (NPC), and as monotherapy for the treatment of adults with recurrent, or metastatic NPC with disease progression on or after platinum-containing chemotherapy.
10月27日，中国生物技术公司及其美国合作伙伴Cohereus BioSciences Inc联合宣布，美国FDA批准Loqtorzi（托帕利单抗-tpzi）与其他药物联合用于成人转移性或复发性局部晚期转移性鼻咽癌（NPC）的一线治疗，或在含铂化疗时或之后具有疾病进展的转移性NPC。
Due to the location of the primary tumor, surgery is rarely an option, and patients with the localized disease are treated primarily with radiation and chemotherapy.
由于原发肿瘤的位置，手术很少是一种选择，局部疾病的患者主要接受放疗和化疗。
According to a press release from the companies, Jong Chul Park, assistant professor at Harvard Medical School and attending physician at the Center for Head and Neck Cancers at Massachusetts General Hospital Cancer Center, said that the drug, a new treatment option demonstrating the ability to significantly improve progress-free survival and overall survival of patients, should quickly emerge as the new standard of care when used in combination with chemotherapy.
根据两家公司的新闻稿，哈佛医学院助理教授、马萨诸塞州总医院癌症中心头颈癌中心的主治医师朴钟哲（Jong Chul Park）表示，该药物是一种新的治疗选择，表明有能力显着提高患者的无进展生存率和总体生存率，当与化疗联合使用时，应迅速成为新的护理标准。
As of the end of March, about two dozen chemotherapy drugs were in active shortage, the fifth most of any drug category, said the University of Utah Drug Information Service.
犹他大学药物信息服务中心表示，截至3月底，约有20多种化疗药物严重短缺，在所有药物类别中排名第五。
However, autologous hematopoietic stem-cell transplantation combined with high-dose chemotherapy can help CAR-T overcome this immunosuppressive microenvironment and promote the proliferation of CAR T-cells, thereby precisely killing cancer.
然而，自体造血干细胞移植结合大剂量化疗可以帮助CAR-T克服这种免疫抑制微环境，促进CAR T细胞的增殖，从而精确杀死癌症。
Chief physician Meng Fankai, a member of the Tongji CAR-T therapy team, said, "As a typical case of lymphoma involving the central nervous system, Wu received six cycles of chemotherapy in the local hospital and developed memory impairment.
同济CAR-T治疗团队成员孟凡凯主任医师说：“作为中枢神经系统淋巴瘤的典型病例，吴在当地医院接受了六个周期的化疗，并出现了记忆障碍。
They collected stem cells and concurrently performed high-dose chemotherapy.
他们收集干细胞，同时进行高剂量化疗。
"Market launch of the drug provided an opportunity for terminal-stage lung cancer patients to have a first-line therapy, a better option than existing chemotherapy," Zhang said.
张说：“这款药物的上市，让末期肺癌患者拥有了第一线治疗方案，比现有的化疗方案更具优势。”
Biotech company BeiGene Ltd announced Thursday its anti-PD-1 antibody tislelizumab has received approval from the country's National Medical Products Administration for use in combination with two chemotherapy regimens as a first-line treatment for patients with advanced squamous non-small cell lung cancer.
生物科技公司 BeiGene Ltd 周四宣布，其抗 PD-1 抗体替雷利珠单抗已获得中国国家药品监督管理局的批准，可用于与两种化疗方案联合使用，作为晚期鳞状非小细胞肺癌患者的一线治疗。
In Phase 3 trial in this indication, tislelizumab, combined with standard chemotherapy, demonstrated a clinically meaningful benefit as assessed by progression-free survival and response rates, Wang saidA total of 360 patients were randomized 1:1:1 to receive tislelizumab in combination with either chemotherapy regimen or chemotherapy alone during the trial.
王教授表示，在这一适应症的第三期试验中，替雷利珠单抗联合标准化疗方案显示出了具有临床意义的益处，体现在无进展生存期和缓解率上。试验中，共有360名患者以1:1:1的比例被随机分组，分别接受替雷利珠单抗联合任一化疗方案或单纯化疗治疗。
In China, we witnessed high growth this year as well particularly because the market space for target therapy is still vast in relation to cancer as many patients still resort to traditional chemotherapy.
Upon filing a new drug application, the drug was granted priority review status by the Center for Drug Evaluation, which is part of China's National Medical Products Administration, for the second line maintenance treatment of adult patients with recurrent epithelial, ovarian, fallopian tube or primary peritoneal ovarian cancer who are in a complete or partial response to platinum-based chemotherapy.
Early detection and precision care can reduce cancer deaths and the burdens of disease, and minimal invasive treatment is receiving more clinical awareness because it is lower in cost, results in fewer complications, and retains more human tissues and protection of immunity, compared with other treatments, such as surgery and chemotherapy, according to Zheng Jiasheng, chairman of the alliance.
A groundbreaking new cancer drug with the power to shrink tumours could soon provide an alternative to chemotherapy.
Mucosal melanoma is not responsive to traditional chemotherapy and responds poorly to immunosuppressive monotherapy.
The use of Toripalimab in combination with Axitinib to treat patients with advanced mucosal melanoma who have not received chemotherapy can achieve an objective response rate of 48.3 percent and a disease control rate of 86.2 percent.
The drug is for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal ovarian cancer who are in a complete or partial response to platinum-based chemotherapy.
They are first-line treatment of patients with advanced squamous non-small cell lung cancer in combination with chemotherapy, first-line treatment of patients with advanced non-squamous NSCLC in combination with chemotherapy, and previously treated unresectable hepatocellular carcinoma.
The newly approved indication, for patients suffering from locally advanced or metastatic urothelial carcinoma with PD-L1 high expression whose disease progressed during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy, is the first in a solid tumor indication.
未经许可，严禁转发。QQ交流群：688169419